Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilia Scalzulli

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|November 27, 2024
Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategiesAlessandro Costa, Emilia Scalzulli, Massimo Breccia
Drugs of Today (Barcelona, Spain : 1998)|October 28, 2022
Asciminib in chronic myeloid leukemiaGiovanni Manfredi Assanto, Emilia Scalzulli, Massimo Breccia
Mediterranean Journal of Hematology and Infectious Diseases|September 13, 2017
Solitary PlasmacytomaSara Grammatico, Emilia Scalzulli, Maria Teresa Petrucci
Expert Opinion on Investigational Drugs|June 16, 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Emilia Scalzulli, et al.
Blood Reviews|April 8, 2020
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?Emilia Scalzulli, Sara Pepe, Gioia Colafigli, et al.
Expert Opinion on Pharmacotherapy|February 27, 2018
Proteasome inhibitors for the treatment of multiple myelomaEmilia Scalzulli, Sara Grammatico, Federico Vozella, et al.
Future Oncology (London, England)|February 12, 2025
Asciminib in the treatment of chronic myeloid leukemia in chronic phaseAlessandro Costa, Emilia Scalzulli, Maria Laura Bisegna, et al.
Expert Review of Hematology|February 8, 2021
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsFabio Efficace, Marco Vignetti, Francesco Sparano, et al.
International Journal of Hematology|August 5, 2022
Asciminib as a third line option in chronic myeloid leukemiaAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Therapeutic Advances in Hematology|March 12, 2019
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemiaMatteo Molica, Emilia Scalzulli, Gioia Colafigli, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|November 27, 2024
Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategiesAlessandro Costa, Emilia Scalzulli, Massimo Breccia
Drugs of Today (Barcelona, Spain : 1998)|October 28, 2022
Asciminib in chronic myeloid leukemiaGiovanni Manfredi Assanto, Emilia Scalzulli, Massimo Breccia
Mediterranean Journal of Hematology and Infectious Diseases|September 13, 2017
Solitary PlasmacytomaSara Grammatico, Emilia Scalzulli, Maria Teresa Petrucci
Expert Opinion on Investigational Drugs|June 16, 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Emilia Scalzulli, et al.
Blood Reviews|April 8, 2020
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?Emilia Scalzulli, Sara Pepe, Gioia Colafigli, et al.
Expert Opinion on Pharmacotherapy|February 27, 2018
Proteasome inhibitors for the treatment of multiple myelomaEmilia Scalzulli, Sara Grammatico, Federico Vozella, et al.
Future Oncology (London, England)|February 12, 2025
Asciminib in the treatment of chronic myeloid leukemia in chronic phaseAlessandro Costa, Emilia Scalzulli, Maria Laura Bisegna, et al.
Expert Review of Hematology|February 8, 2021
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsFabio Efficace, Marco Vignetti, Francesco Sparano, et al.
International Journal of Hematology|August 5, 2022
Asciminib as a third line option in chronic myeloid leukemiaAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Therapeutic Advances in Hematology|March 12, 2019
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemiaMatteo Molica, Emilia Scalzulli, Gioia Colafigli, et al.
Pageof 8